Mizuho Securities analyst Difei Yang maintained a Buy rating on Concert Pharma (NASDAQ: CNCE) today and set a price target of $27. The company’s shares opened today at $20.
Concert Pharmaceuticals, Inc. (cnce): bullish rating reiterated CNCE – Mizuho securities reiterates buy rating, $27 PT. This price target represents a 34.73% upside over the stock’s previous closing price of $20.04.
After JMP Securities and H.C. Wainwright gave Concert Pharma (NASDAQ: CNCE) a Buy rating last month, the company received another Buy, this time from Mizuho Securities.Analyst Difei Yang maintained a Buy rating on Concert Pharma today and set a price target of $26.The company’s shares closed yesterday at $12.59, close to its 52-week low of $12.32.
Mizuho Securities reissued its Buy rating and $26 price target on Concert Pharma after trial data from a competitor confirmed their view Concert is ‘best in class’ in their space. Here is the.
Mizuho Securities analyst Didei Yang lowered the price target on Concert Pharmaceuticals (NASDAQ: CNCE) to $26.00 (from $27.00) while maintaining a Buy rating following earnings.
Biogen (BIIB): Mizuho sets price target to $400.00 with buy rating. See our coverage of BIIB. Nektar Therapeutics (NKTR): J P Morgan Chase & Co reiterates buy with target of $44. See also our coverage.
Concert Pharma (NASDAQ:CNCE) Rating Reaffirmed. They currently have a $26 target price per share on Concert Pharma (NASDAQ:CNCE). The target price by Mizuho Securities would suggest a potential upside of 78.57 % from the company’s last close price. This has been revealed to investors in a research note on Friday morning.
Mizuho Securities Keeps a Buy Rating on concert pharma (cnce) 2019-03-01, 09:10:00 smarteranalyst.com "We continue to see upside in CNCE shares, and believe limited value is currently.
Insider Trading information for CNCE is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note: An FPI is exempt of filing insider holdings with t.
Concert Pharma (CNCE) received a Buy rating reiterated by Mizuho Securities last week. The price target was set at $27. The analyst Difel Yang expressed optimism on the success of CTP-543 in moderate to severe alopecia areata (data is expected in Q4 this year).